Sacituzumab govitecan (Trodelvy) now has regular FDA approval for people with locally advanced or metastatic triple-negative breast cancer (TNBC), including those with brain metastases. The update follows last year’s accelerated approval of the drug for people with TNBC.
Pharmaceutics, Free Full-Text
Triple negative breast cancer: Pitfalls and progress
ADC Drug Trodelvy Shows Positive Efficacy In three Types of Cancers
Elina Armani on LinkedIn: #nanoparticles #drugdelivery #sln
Triple Negative Breast Cancer Archives - Tigerlily Foundation
FDA Approvals National Cancer Institute
Clinical Review - Sacituzumab Govitecan (Trodelvy) - NCBI Bookshelf
EX-99.2
Frontiers Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer
Sacituzumab Govitecan Moves to Second-Line Therapy for Metastatic
/)